Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

Esperion: What Does A Cut In Praluent Pricing Mean?

16h seekingalpha
Esperion (NASDAQ:ESPR) recently reported data from Study 4 of its Phase III clinical program with its bempedoic acid in statin-intolerant patients with atherosclerotic cardiovascular disease (ASCVD) or at high risk of ASCVD with elevated low-density lipoprotein cholesterol (LDL-C). The study met the primary endpoint, with patients on the 180 mg dose seeing a statistically significant 28% additional lowering of LDL-C compared to placebo at week 12. (81-0)

Tops Of 44 'Safer' Dividend Nasdaq Equities: Comcast By Gain; Vodafone By Yield For March

21h seekingalpha
46 of 52 NASDAQ Index dividends were presumed "safer" because they showed positive one-year returns and free cash flow yields greater than dividend yields as of 3/15/17. (241-0)

Goldman has ideas on how to make money by anticipating M&A deals - MarketWatch

2018-03-18 marketwatch
Investors can use movements in options to gauge expectations for M&A — and profit from them (148-0)

Top 52 Nasdaq Stocks By Yield, Upside & Gains For March

2018-03-17 seekingalpha
"The Nasdaq-100 Index includes 100 of the largest domestic and international non-financial companies listed on The Nasdaq Stock Market based on market capitalization." 52 pay dividends. (208-0)

Even More Biopharma Catalysts Coming Through the End of March

2018-03-17 247wallst
Biotech and pharmaceutical companies are generally involved in the lengthy process of getting their drug candidates to market through clinical trials. The amount of risk involved ranges from fair to great, should a study come back negative or a candidate not be approved. Conversely, if a drug is approved or passes a clinical trial, there can be massive upside. (187-3)

U.S. Biotech/Pharma Sector Daily Observations Letter: March 13, 2018

2018-03-14 seekingalpha
Anthera Pharmaceuticals (ANTH) is trading at a market cap of just $11.3 million (with cash reserves of $16M and net operating loss carryforwards of $7.5M). (85-0)

Is Amgen Inc. (AMGN) a Great Stock for Value Investors?

2018-03-14 zacks
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value? (79-0)

Merck's Keytruda Gets Priority Review for Cervical Cancer

2018-03-14 zacks
Merck & Co., Inc. (MRK - Free Report) announced that a supplemental Biologics License Application (sBLA) for its anti-PD-1 therapy, Keytruda, has been accepted under priority review by the FDA. (79-0)

Sell for Amgen (AMGN) This Week

2018-03-13 investorplace
Amgen (AMGN) remains a Sell this week based on the latest market intelligence, and comparative pricing of its shares. Amgen Inc's (NASDAQ:AMGN) current Sell recommendation is based on reasoning that considers a ranking in the company's sector group that is in the bottom quarter, a ranking in its industry group that is in the bottom quarter, a numerical calculation of risk/reward that is below average, and an analytical score that is well below average. (67-0)

The Amgen, Inc. Stock Spring Is About to Pop | InvestorPlace

2018-03-13 investorplace
The bull market beat is trying to continue rolling on today, despite heavy headlines, with the Nasdaq Composite looking to stretch higher for the eighth day in a row. But with overbought pressures climbing, low-risk entries are disappearing faster than White House advisers. (67-0)

3 Biotech Stocks With Rising Earnings Estimates Post Q4

2018-03-13 zacks
The Q4 earnings season for the pharma/biotech sector was scattered with a few small biotech companies yet to report. The releases so far provide us with a clear picture of the sector’s performance. (193-3)

Odyssey Outcomes: Making Regeneron's Stock Great Again?

2018-03-13 seekingalpha
At least as important to me, they announced a favorable cost-benefit opinion from an independent organization. (88-0)

Major Biotechs: Tough Call for Short Sellers

2018-03-12 247wallst
The short interest data are out for the most recent settlement date, February 28. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, with big potential upside and big potential downside. (287-0)

Regeneron and Sanofi Announce Positive Data on Praluent

2018-03-12 zacks
Regeneron Pharmaceuticals, Inc. (REGN - Free Report) and partner Sanofi (SNY - Free Report) announced positive results from the ODYSSEY OUTCOMES trial on Praluent during a late-breaker session at the American College of Cardiology's 67th Annual Scientific Session in Orlando, FL. (82-0)

CUSIP: 031162100